Business

Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025

Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for

articleAddex Therapeutics LtdApril 24, 20253/company/addex-therapeutics-ltd/news/addex-therapeutics-to-release-full-year-2024-financial-results-and-host-conference-call-on-april-25-2025
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025

About this update from Addex Therapeutics Ltd

[{"type":"image","alt":"Addex Therapeutics","displaySize":"","headline":null,"caption":"Addex Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":231,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i1_J.LrQ5M.Eo1NBP2WLjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7","width":231,"height":115}},"lazy":false},{"type":"text","content":"Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.","length":594,"tagName":"p"},{"type":"text","content":"Title:   Addex Therapeutics Full-Year 2024 financial results and corporate update Date:  April 25, 2025Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT)","length":172,"tagName":"p"},{"type":"text","content":"Joining the Conference Call:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.","length":210,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.","length":267,"tagName":"p","attribs":{}}]}],"tagName":"ol","bulletedList":false,"length":477},{"type":"text","content":"Webcast registration URL: https://edge.media-server.com/mmc/p/9dcowszvConference call registration URL: https://register-conf.media-server.com/register/BI125c71cb643c4527914...

More updates from Addex Therapeutics Ltd

biopharmaceutical companyneurological disordersTim Dyerallosteric modulatorsAddexdeveloping a portfolio